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Abstract: Hypertension, atherothrombosis, myocardial infarction, stroke, peripheral vascular 
disease, and renal failure are the main manifestations of cardiovascular disease (CVD), the 
leading cause of death and disability in developed countries. Continuing insight into the patho-
physiology of CVD can allow identiﬁ  cation of effective therapeutic strategies to reduce the 
occurrence of death and/or severe disabilities. In this context, a healthy endothelium is deemed 
crucial to proper functioning and maintenance of anatomical integrity of the vascular system in 
many organs. Of note, epidemiologic studies indicate that the incidence of CVD in women is 
very low until menopause and increases sharply thereafter. The loss of protection against CVD 
in post-menopausal women has been chieﬂ  y attributed to ovarian steroid deﬁ  ciency. However, 
besides steroids, the ovary also produces the peptide hormone relaxin (RLX), which provides 
potent vasoactive effects which render it the most likely candidate as the elusive physiologi-
cal shield against CVD in fertile women. In particular, RLX has a speciﬁ  c relaxant effect on 
peripheral and coronary vasculature, exerted by the stimulation of endogenous nitric oxide 
(NO) generation by cells of the vascular wall, and can induce angiogenesis. Moreover, RLX 
inhibits the activation of inﬂ  ammatory leukocytes and platelets, which play a key role in CVD. 
Experimental studies performed in vascular and blood cell in vitro and in animal models of 
vascular dysfunction, as well as pioneer clinical observations, have provided evidence that RLX 
can prevent and/or improve CVD, thus offering background to clinical trials aimed at exploring 
the broad therapeutic potential of human recombinant RLX as a new cardiovascular drug.
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cardiovascular disease
The endothelium as a key player in vascular health 
and disease
Hypertension, atherothrombosis, myocardial infarction, stroke, peripheral vascular 
disease, and renal failure are the main manifestations of cardiovascular disease (CVD), 
which is the leading cause of death and disability in most developed countries, also 
due to the progressive increase in people’s life span and expectancy (Wey 1992). 
Therefore, action should be taken to prevent CVD before its signs and symptoms 
appear or severe outcome, such as myocardial infarction or stroke, is experienced. In 
this context, there is a general agreement between basic and clinical scientists that a 
healthy endothelium is crucial to allow proper functioning and maintenance of anatomi-
cal integrity of the vascular system in many organs, including the heart, brain, kidney, 
lung, and placenta. Conversely, damaged or dysfunctional endothelium substantially 
contributes to the pathogenesis and complications of CVD (Mensah 2007; Osto et al 
2007). Public health interventions for health promotion and prevention of CVD and 
its associated risk factors often target the endothelium, and further understanding of 
endothelial function can help develop innovative approaches.
Once viewed as a mere cell lining of the blood vessels serving as a barrier between 
the blood and the tissue extracellular matrix, the endothelium has been more recently 
recognized to be far more complex and functional (Figure 1). In fact, endothelial Vascular Health and Risk Management 2008:4(3) 516
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cells play a major role in the regulation of vascular tone, 
hemostatic/ﬁ  brinolytic balance, angiogenesis, and leuko-
cyte trafﬁ  cking (Mensah 2007). Many of the functional 
properties of the endothelial cells are attributable to their 
unique ability to synthesize and release a variety of vasoac-
tive mediators, including nitric oxide (NO), a gaseous free 
radical and key signalling molecule (Moncada et al 1991). 
Intact endothelial cells constitutively express NO synthase 
III, which continuously generates nanomolar NO amounts. In 
turn, endothelium-derived NO accounts for vascular smooth 
muscle cell relaxation and vasodilatation (Palmer et al 1987; 
Moncada et al 1991), angiogenic response (Ziche et al 
1994), and anti-adhesive properties of the inner endothelial 
surface to platelets (Radomski et al 1987) and leukocytes 
(Kubes et al 1991) by down-regulation of endothelial cell 
adhesion molecules (Sluiter et al 1993). Therefore, failure 
of endothelial NO pathway and increased oxidative stress 
with loss of the protective effect of NO tips the endothelial 
cell balance towards a pro-atherogenic and pro-thrombotic 
milieu (Nedeljkovic et al 2003) and can initiate a vicious 
cycle of events that result in vasomotor dysfunction and 
vascular inﬂ  ammation, which are essential components in 
the initiation and evolution of atherosclerosis (Napoli et al 
2006). On these grounds, it is conceivable that agents that 
increase NO availability and reduce endothelial dysfunction 
may decrease susceptibility to CVD.
A typical paradigm of the key importance of endothelial 
integrity for normal vascular function is represented by the 
pathogenic cascade initiated and sustained by cigarette smoke 
(Ambrose and Barua 2004). Smoking is known to increase the 
incidence of peripheral and coronary artery diseases, myo-
cardial infarction and reduced foeto-placental perfusion and 
foetal growth restriction (Jonas et al 1992; Price et al 1999; 
Kalinka et al 2005; Zdravkovic et al 2005). Experimental 
and clinical investigations have provided evidence that 
cigarette smoke causes endothelial cell dysfunction, mainly 
consistent in decreased generation and bioavailability of 
NO, which results in defective endothelium-dependent 
vasodilatation and increased susceptibility to leukocyte and 
platelet adhesion (Barua et al 2001, 2002). Cigarette smoke 
is an example of the many dietary and lifestyle habits and 
inherited or acquired diseases predisposing to CVD, which 
also include obesity, hyperlipemia, diabetes, hypertension, 
vasculitis, and so on. In all these cases, the dysfunctional 
endothelium emerges as a crucial pathogenic factor and 
potential target for early diagnostic, preventative, and cura-
tive strategies.
Gender-related differences in CVD 
and the role of ovarian sex 
hormones
Clinical and epidemiologic studies have shown that men 
and women suffering from CVD differ in pathophysiol-
ogy, time for onset, and prognosis upon treatment. The 
incidence of CVD in women is very low until menopause 
and increases sharply thereafter to become similar to men, 
but with a 10–20-year delay (Wenger et al 1993; Tunstall 
et al 1994; Hu et al 2000). The epidemiologic ﬁ  ndings have 
been strengthened by the observation that, during fertile 
life, women have better endothelial function and vascular 
reactivity and higher NO biosynthesis than age-matched men 
(Forte et al 1998; Sader and Celermajer 2002). Female sex 
hormones have been obviously implicated in the protective 
effects of gender on the vasculature (Orshal and Khalil 2004; 
Mendelsohn and Karas 2005). Most of the existing literature 
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is focused on ovarian steroids, estrogen and progesterone, 
which can inﬂ  uence vascular functions by multiple mecha-
nisms. Estrogen and progesterone receptors are expressed by 
the vascular endothelium and smooth muscle (Khalil 2005): 
the interaction of ovarian steroids with cytosolic receptors 
triggers genomic effects leading to angiogenesis, endothelial 
NOS III up-regulation and smooth muscle growth inhibi-
tion; on the other hand, stimulation of plasma membrane 
receptors by these hormones initiates non-genomic effects 
that stimulate endothelium-dependent vasorelaxation via 
NO-cGMP, prostacyclin-cAMP and hyper-polarization 
pathways (Hayashi et al 1995; Khalil 2005; Siow et al 2007). 
Moreover, ovarian steroids can also inﬂ  uence vascular func-
tion by receptor-independent pathways, including direct 
antioxidant effects due to the presence of a phenolic group in 
their molecules (Siow et al 2007), as well as indirect effects 
mediated by hypothalamic-pituitary feed-back inhibition 
(Sader and Celermajer 2002).
On the above grounds, the loss of protection against CVD 
in post-menopausal women has been chieﬂ  y attributed to the 
deﬁ  ciency of ovarian steroids. Consequently, menopausal 
replacement therapy has been widely advocated for primary 
and secondary prevention (Grodstein et al 1996). However, 
estrogen or progesterone have not been clearly identiﬁ  ed 
as the protective agents in women. In fact, the results of 
estrogen/progestin replacement therapy are still controversial 
and under discussion (Herrington et al 2000; Rosano et al 
2006). The conclusions drawn from randomized studies car-
ried out by the Heart and Estrogen/progestin Replacement 
Study (HERS) Research Group (Hulley et al 1998) and the 
Women’s Health Initiative Investigators (WHI) (Manson 
et al 2003), enrolling large cohorts of subjects, concur to 
indicate that estrogen plus progestin does not confer cardiac 
protection and may even increase the risk of CVD among 
generally healthy post-menopausal women, especially during 
the ﬁ  rst year after the initiation of hormone use, most likely 
due to unfavorable effects of ovarian steroids upon platelet 
activation and coagulation (Bonnar 1987). Therefore, it has 
been recommended that estrogen/progestin replacement 
should not be prescribed for the prevention of cardiovascular 
disease (Manson et al 2003).
This ostensible paradox can ﬁ  nd a logical explanation if 
bearing in mind that menopause causes the loss of ovarian 
function, which does not merely imply the cessation of estro-
gen and progesterone production. In fact, besides steroids, 
the ovary produces the peptide hormone relaxin (RLX), 
which also has vasoactive properties. RLX is secreted by 
the corpus luteum and is secreted at detectable levels in the 
blood of cycling and pregnant women, being absent – or at 
least undetectable with the current assay methods – in post-
menopausal women and in men (O’Byrne et al 1978; Eddie 
et al 1986; Khan-Dawood et al 1989; Stewart et al 1990; 
Winslow et al 1992). Could RLX be the elusive natural or 
physiological shield against CVD in fertile women? In the 
following chapters, the many points in favour of this hypoth-
esis will be summarized and reviewed.
RLX, its cognate molecules, 
and their receptors
RLX was discovered in 1926 by Frederick Hisaw, who 
observed that the injection of serum from pregnant guinea 
pigs or rabbits into virgin guinea pigs induced signiﬁ  cant 
elongation of the interpubic ligament, attributed to stimula-
tion of collagen turn-over (Hisaw 1926). Later on, he and 
his colleagues isolated from pregnant sow corpora lutea 
a peptide responsible for the observed relaxant effect on 
pubic symphisis and named it ‘relaxin’ (Fevold et al 1930).
It is worth noting that the collagen remodeling properties 
of RLX ﬁ  rst highlighted by Hisaw have been conﬁ  rmed by 
many subsequent investigations (Unemori and Amento 1990; 
Unemori et al 1992, 1993, 1996; Garber et al 2001; Williams 
et al 2001; McDonald et al 2003; Samuel et al 2003) and 
remain as a hallmark of RLX and a paradigm of its speciﬁ  c 
biological effects (Sherwood 2004).
RLX has been long included in the insulin hormone 
superfamily because of structural homologies with insulin: 
both peptides have similar 6 kDa molecular weights and are 
composed of A and B chains stabilized by inter- and intra-
chain disulﬁ  de bonds (Schwabe and Büllesbach 1994). More 
recently, however, it has been deﬁ  nitely ascertained that 
RLX is a member of a peptide hormone family that diverged 
from insulin early in vertebrate evolution; therefore, RLX 
has been assigned to a speciﬁ  c hormone family, termed the 
RLX peptide family, which includes three different RLXs, 
H1, H2 and H3, as well as insulin-like peptide (INSL)3, 
INSL4, INSL5 and INSL6 (Bathgate et al 2003; Samuel 
et al 2006). In humans, 3 separate RLX genes have been 
found and designated RLN1, RLN2 and RLN3 (Bathgate 
et al 2003; Samuel et al 2006). The peptide encoded by the 
RLN2 gene, H2 RLX, is the major circulating form and is 
produced mainly in the corpus luteum (Hudson et al 1984). 
Circulating RLX accounts for most of the known biological 
effects of the hormone in humans and experimental animals. 
RLX acts on the female reproductive system as well as 
on non-reproductive targets, including the cardiovascular 
system and the connective tissue (Bani 1997; Conrad and Vascular Health and Risk Management 2008:4(3) 518
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Novak 2004; Sherwood 2004; Dschietzig et al 2006; Samuel 
et al 2006; Nistri et al 2007).
RLX is the ligand for two leucine-rich repeat-containing 
G-protein coupled receptors (LGRs), LGR7 and LGR8 (Hsu 
et al 2002), now classiﬁ  ed as relaxin family peptide recep-
tors 1 and 2 (RXFP1 and RXFP2), respectively (Bathgate 
et al 2006). RXFP1 is the main and most speciﬁ  c H2 RLX 
receptor, but it is also able to bind H1 and H3 RLX, although 
with less afﬁ  nity. On the other hand, RXFP2 chieﬂ  y binds 
INSL3 and also H1 and H2 RLX, but with less afﬁ  nity (Hsu 
et al 2002; Sudo et al 2003). These receptors have been 
found on most if not all RLX target tissues and cells, and 
are abundantly expressed in the reproductive, nervous, renal 
and cardiovascular systems (Hsu et al 2002). More recently, 
other G protein-coupled receptors for peptides of the relaxin 
family have been discovered and termed RXFP3 (formerly 
GPCR135) and RXFP4 (formerly GPCR142) (Bathgate 
et al 2006). RXFP3 binds H3 RLX with high afﬁ  nity (Liu 
et al 2003a) while RXFP4 binds H3 RLX (Liu et al 2003b) 
and also INSL5 (Liu et al 2005). Moreover, RLX has been 
reported to act as an agonist for cytoplasmic glucocorticoid 
receptors, thereby exerting possible cortisol-like effects 
(Dschietzig et al 2004). Binding of RLX to its surface recep-
tor results in the activation of multiple intracellular response 
pathways, which include cAMP and NO as second messen-
gers (Hsu et al 2002; Nistri and Bani 2003). In particular, 
the observation that RLX can up-regulate NO biosynthesis in 
several of its targets underscores its potential as cardiovascu-
lar hormone, NO being a key regulator of vascular function 
(Moncada et al 1991; Nathan 1992).
RLX and the vascular system
Peculiarly, the ﬁ  rst reports on the ability of RLX to inﬂ  uence 
blood vessels came from clinical rather than basic research. 
During the late 1950s and early 1960s, the Warner-Chilcott 
Laboratories provided an impure preparation of porcine RLX, 
commercially available as Releasin, and supported studies 
in humans that examined the use of relaxin as a therapeutic 
agent for scleroderma, cervical ripening and premature 
labor, based on its collagen-remodeling properties. Releasin, 
injected intramuscularly to patients suffering for peripheral 
vascular diseases and Raynaud’s syndrome, caused a dra-
matic, albeit transient, amelioration of symptoms and signs 
of ischemia (Casten and Boucek 1958; Casten et al 1960). 
These effects were attributed to increased compliance of the 
blood vessels due to loosening of their adventitial extracel-
lular matrix. However, Casten and colleagues also reported 
that, in some patients who also suffered for ischemic heart 
disease, Releasin treatment led to the reduction of the daily 
glyceryl trinitrate requirements. Retrospectively, this impor-
tant observation clearly suggests that RLX does have a direct, 
dilatory effect on peripheral and coronary vasculature. Sub-
sequent studies in monkeys by the Hisaw’s group described 
an enlargement of endometrial arterioles and capillaries 
(Dallenbach-Hellweg et al 1966) and provided ﬁ  rst evidence 
for an angiogenic effect of RLX on endothelial cells of the 
endometrial blood vessels (Hisaw 1967). Deﬁ  nite recogni-
tion of the blood vessels as speciﬁ  c RLX targets came from 
the identiﬁ  cation of RLX binding sites/receptors on vascular 
cells in reproductive and non-reproductive organs (Min and 
Sherwood 1996; Kohsaka et al 1998; Hsu et al 2002).
Vasodilatation may be regarded as an additional, speciﬁ  c 
hallmark of RLX, as it has been observed in many target 
organs and tissues, regardless of gender. RLX-induced vaso-
dilatation mainly involves the distal segments of the vascular 
tree, namely arterioles provided with a smooth muscle coat 
as well as capillaries and post-capillary venules, which lack 
smooth muscle in their wall. Of note, RLX promotes vasodi-
latation in reproductive organs, such as the uterus (Vasilenko 
et al 1986; Bani G et al 1995) and the mammary gland (Bani 
et al 1988), as well as in non-reproductive targets, including 
mesocaecum (Bigazzi et al 1986), kidney (Danielson et al 
1999, 2000; Novak et al 2001), liver (Bani et al 2001), lung 
(Bani et al 1997), and heart (Bani Sacchi et al 1995; Masini 
et al 1997). Vasodilatation appears as a physiologic effect 
of RLX since it is fully manifest at hormone concentrations 
which are in the nanomolar range, similar to the RLX blood 
levels of normal human pregnancy (O’Byrne et al 1978; 
Eddie et al 1986). RLX is extremely potent as a vasorelax-
ant: in the isolated, perfused rat and guinea pig heart, the 
dose-dependent increase in coronary ﬂ  ow induced by RLX is 
signiﬁ  cantly higher than that obtained with similar doses of 
typical vasodilatatory agents such as acetylcholine or sodium 
nitroprusside (Bani Sacchi et al 1995); in the mesocaecum, 
RLX counteracted similar concentrations of norepinephine 
(Bigazzi et al 1986). Vasodilatation also emerges as a pri-
mary effect of RLX and is not secondary to tissue growth 
stimulation, as it could be appreciated even in the absence 
of any growth response.
Of note, the vasodilatatory effects of RLX are most 
prominent in vasoconstricted blood vessels, rather than in 
normal blood vessels, suggesting that this hormone could act 
as a natural regulator of vascular tone and a shield against the 
derangements of vascular reactivity. In the rat kidney, RLX 
reduces the myogenic activity of small arteries and blunts the 
vasoconstrictive response to angiotensin II, in both genders Vascular Health and Risk Management 2008:4(3) 519
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(Danielson et al 1999, 2000; Novak et al 2001). In a rat 
model of renal artery ligation, RLX counteracts the increase 
in systemic blood pressure due to activation of the renin-
angiotensin system (Garber et al 2003). In spontaneously 
hypertensive rats (SHR), but not normotensive rats, RLX 
reduces blood pressure and blunts the response of mesenteric 
vessels to vasoconstrictors (St Louis et al 1985).
Besides vasodilatation, RLX can also induce angio-
genesis in some target organs, as suggested by the pioneer 
ﬁ  ndings by Hisaw (1967), using partially puriﬁ  ed RLX. In 
human endometrial cells in vitro, RLX induces the produc-
tion of potent angiogenic molecules such as basic ﬁ  broblast 
growth factor (bFGF) and vascular endothelial growth fac-
tor (VEGF) (Unemori et al 1999). In a rat model of chronic 
myocardial infarction, systemic infusion of RLX potentates 
bFGF mRNA expression in the peri-infarct region by both 
cardiomyocytes and ﬁ  broblasts (Lewis et al 2001). Similarly, 
in a swine model of post-infarcted heart, locally produced 
RLX by RLN2 gene-transfected myoblasts grafted into the 
post-ischemic myocardium, causes a signiﬁ  cant increase in 
microvessel density and over-expression of VEGF mRNA 
by the host cardiac cells (Formigli et al 2007). Thus, RLX, 
by promoting vasodilation and, at least in some conditions, 
angiogenesis could inﬂ  uence the perfusion of many target 
organs.
Sound experimental evidence exists that the vasoactive 
action of RLX can be chieﬂ  y ascribed to the prompt synthe-
sis and release of the potent vasodilator NO (Moncada et al 
1991; Nathan 1992) by blood vessel cells. In vitro studies 
have shown that addition of RLX to the culture medium of 
endothelial cells from rat coronaries and human umbilical 
vein and of bovine vascular smooth muscle cells causes a 
dose-dependent increase in the production of NO and in 
the intracellular levels of cGMP (Bani et al 1998a; Failli 
et al 2001; Quattrone et al 2004), the mediator of the cell 
response to NO (Ignarro 1991). This is accompanied by a 
concurrent decrease in cytosolic Ca2+ concentration and by 
morphological changes in cell shape and cytoskeletal con-
tractile microﬁ  laments consistent with cell relaxation (Bani 
et al 1998a). RLX activates endogenous NO biosynthesis 
by increasing the expression and activity of inducible NO 
synthase (NOS II) in both cell types (Bani et al 1998a; Failli 
et al 2001; Quattrone et al 2004). In keeping with these ﬁ  nd-
ings, RLX has been found to up-regulate endothelin type-B 
(ETB) receptors and the release of NO on the renal vascular 
endothelium in the rat in vivo (Conrad et al 1999). Based 
on the current literature, there are multiple pathways by 
which the G protein-coupled RLX receptors can stimulate 
NO generation (Nistri and Bani 2003). In endothelial cells, 
constitutive NO synthase (NOS III) activity is stimulated by 
vasoactive agonists and hormones, such as acetylcholine, 
bradykinin and estrogens, which also act by speciﬁ  c mem-
brane-associated G protein-coupled receptors (Liu et al 1995; 
Vanhoutte 1997; Wyckoff et al 2001). The classical signaling 
pathway involves G protein βγ subunits that, through phos-
phoinositide 3-kinase (PI3-K), switch on protein kinase B 
(Akt), which in turn activates NOS III by phosphorylation at 
Ser-1179 (Igarashi and Michel 2001). Another mechanism, 
which may either coexist in the same cell or be alternatively 
operating in different cell types, could involve cAMP and 
the inducible NOS II isoform. In rat vascular smooth muscle 
cells, G protein-coupled receptor-activated adenylate cyclase 
and the consequent rise in cAMP upregulates protein kinase 
A (PKA) activity (Kim et al 2002). In turn, PKA is able to 
phosphorylate and inactivate IkB-α, the inhibitor subunit 
of the transcription factor NF-κB, thus allowing NF-κB to 
translocate into the nucleus and to promote the expression of 
NOS II (Grimm and Baeuerle 1993). This latter mechanism 
may be also operating in the noted RLX vascular target cells, 
in which induction of NOS II expression and high-output, 
sustained NO generation have been observed (Bani et al 
1998a; Failli et al 2001). It has been also suggested that RLX 
may indirectly activate the NO pathway through the stimula-
tion of extracellular matrix-remodeling. In fact, RLX-induced 
collagenase activation could convert big endothelin (ET)-1 
into bioactive ET1–32, which in turn binds to and activates 
ETB receptors, thereby inducing NOS III activation and NO 
release (Conrad and Novak 2004).
Whichever intracellular mechanism is involved in the up-
regulation of endogenous NO generation by vascular cells, 
RLX clearly emerges from the above studies as a major vaso-
active hormone and potential drug able to inﬂ  uence vascular 
tone and, consequently, organ and tissue perfusion.
Relaxin and vascular dysfunction
As summarized in the introduction, endothelial dysfunction is 
a crucial event in the initiation and evolution of atherosclero-
sis and CVD (Napoli et al 2006). The damaged endothelium 
becomes unable to generate vasoactive autacoids, chieﬂ  y 
NO and prostaglandins, and loses its physiological function 
to control vasomotion and blood cell adhesion (Nedeljkovic 
et al 2003). Thence, vasospasm and ischemia on one hand, 
and recruitment and activation of inﬂ  ammatory leukocytes 
and platelets on the other hand, can occur and cause overall 
vascular and organ injury and degeneration. Multiple lines of 
evidence, both experimental and clinical, converge to suggest Vascular Health and Risk Management 2008:4(3) 520
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that RLX may beneﬁ  cially interfere with this pathogenic 
cascade (Figure 2).
Our previous in vitro studies on vascular endothelial cells 
suggest that RLX could sustain endogenous NO generation 
by an alternate pathway to the constitutive NOS III, ie, by the 
expression of inducible NOS II (Failli et al 2001; Quattrone 
et al 2004). This mechanism may likely attain biological 
and pharmacological relevance when RLX is administered 
to functional endothelium to prevent the adverse effects of 
the different causes of endothelial failure, but it cannot be 
ruled out that it could also be operating on early damaged 
endothelium, thereby reverting initial NO failure and inter-
rupting the vicious cycle that would further worsen endo-
thelial injury and dysfunction. Sustained endothelial NO 
generation by RLX can counteract vasoconstriction as well 
as leukocyte adhesion and vascular inﬂ  ammation. We have 
recently demonstrated that RLX can reduce the endothelial 
adhesiveness to neutrophils in pro-inﬂ  ammatory conditions 
in vitro by down-regulating early- and late-phase endothe-
lial cell adhesion molecules (Nistri et al 2003). Moreover, 
besides the endothelium, RLX can also inﬂ  uence the other 
aspect of vascular inﬂ  ammation, ie, the leukocytes. In fact, 
RLX has been shown to strongly inhibit the activation of 
neutrophils challenged in vitro with inﬂ  ammatory media-
tors, by reducing oxidative burst, reactive oxygen species 
(ROS) generation and chemotaxis (Masini et al 2004). 
Finally, RLX has been reported to reduce markedly, and in 
a dose-dependent fashion, the aggregation of platelets (Bani 
et al 1995, 2007), which represents another pathogenic pil-
lar of atherosclerosis. These multiple anti-inﬂ  ammatory, 
anti-thrombotic effects of RLX rely on the stimulation of 
endogenous NO generation, but other concurrent mechanisms 
are likely to be involved. As cited in a earlier, it has been 
recently demonstrated that RLX may act as a glucocorticoid 
receptor agonist by a RXFP receptor-independent pathway, 
thereby mimicking some of the anti-inﬂ  ammatory effects of 
cortisol (Dschietzig et al 2004).
The recent literature reports several experimental stud-
ies on animal models of disease whose results validate the 
above theoretical concept that RLX may be beneﬁ  cial in 
Figure 2 Schematic diagram highlighting the role of the endothelium in the pathophysiology of vascular dysfunction and the targets for RLX action, which include i) up-regulation 
of NOS II and endogenous NO production in endothelial and vascular smooth muscle cells, leading to vascular relaxation; reduced expression of endothelial cell adhesion 
molecules; reduced adhesion and activation of neutrophils, leading to diminished oxidative stress and tissue injury; reduced platelet activation; angiogenesis.Vascular Health and Risk Management 2008:4(3) 521
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CVD. In particular, we have provided evidence that RLX, 
administered to isolated, perfused guinea pig hearts or to 
intact rats in vivo, protects the heart against myocardial injury 
caused by ischemia and reperfusion (IR) (Masini et al 1997; 
Bani et al 1998b). During IR, there is a primary damage of 
the coronary endothelium leading to impaired production of 
NO. This triggers a cascade of events, such as vasoconstric-
tion, leukocyte and platelet recruitment, ROS generation and 
oxidative stress, mast cell activation and histamine release 
and so on, which result in myocardial contractile dysfunction 
and, eventually, irreversible myocardial injury (Lefer et al 
1991). RLX, given preventatively before ischemia, caused a 
signiﬁ  cant reduction of the myocardial tissue area damaged 
by post-ischemic reperfusion, as well as reducing the occur-
rence of severe ventricular arrhythmias. RLX also reduced 
myocardial neutrophil accumulation, platelet and mast cell 
activation, ROS-induced tissue injury and histopathological 
signs of irreversible cardiomyocyte and endothelial injury 
(Masini et al 1997; Bani et al 1998b). The cardioprotective 
action of RLX can go beyond the prevention of IR-induced 
myocardial damage and may ﬁ  nd a therapeutic application in 
myocardial infarction. Recently, we used a swine model of 
cardiac IR in which RLX was administered at reperfusion to 
reproduce an adjunctive medical therapy to primary coronary 
angioplasty in patients with acute myocardial infarction. In 
these studies, RLX, given at reperfusion upon a 30-min isch-
emia at doses yielding physiological or juxta-physiological 
plasma concentrations, caused a marked, dose-related reduc-
tion of the main serum markers of myocardial damage as 
well as of the metabolic and histopathological parameters 
of cardiomyocyte injury and apoptosis and myocardial 
inﬂ  ammation. These effects of RLX resulted in increased 
myocardial salvage and improved ventricular performance 
(Bani et al 2005; Perna et al 2005). These ﬁ  ndings provide 
support to the above concept that RLX may be also effective 
on the endothelium damaged by ischemia, likely counteract-
ing the NO failure and preventing severe endothelial injury 
and dysfunction. Our pioneering studies on RLX-induced 
protection in cardiac IR have been conﬁ  rmed and extended 
by a recent study on rats with isoproterenol-induced cardiac 
ischemia, in which the assayed parameters of myocardial 
damage and dysfunction improved markedly upon treat-
ment with exogenous RLX (Zhang et al 2005). Of note, in 
this study, the injured heart also appears to up-regulate the 
production and release of endogenous RLX, providing sup-
port to the view that RLX is a cardiac hormone (Taylor and 
Clark 1994) and may have paracrine effects against cardiac 
ischemic injury and dysfunction (Dschietzig et al 2001). 
As occurs in the heart, RLX has been shown to protect 
against IR-induced injury in other organs, such as the liver 
(Boehnert et al 2005), the small bowel (Masini et al 2006), 
the pancreas (Cosen-Binker et al 2006) and the brain (Wilson 
et al 2006). In all these studies, direct or indirect evidence 
is provided that the protection afforded by RLX relies on its 
effects on the endothelium and often involve endogenous 
NO generation.
From a clinical perspective, evidence for the efﬁ  cacy of 
RLX as a vascular protector emerges from the early studies 
of Casten and colleagues (1960), who successfully used 
RLX to treat patients with peripheral vascular diseases and 
obtained impressive amelioration of peripheral arteriopathy 
and ischemic ulcers. Moreover, in subjects also suffering 
from ischemic heart disease, RLX reduced the need for daily 
nitrovasodilatator therapy. Possible criticisms raised by the 
use of an impure RLX preparation are overridden by a more 
recent observation that clinical grade human recombinant 
RLX, given as merciful therapy to a patient with severe 
idiopathic occlusive peripheral arterial disease of the lower 
limbs, caused a marked, long-lasting amelioration of both 
subjective symptoms and objective clinical and instrumental 
signs (Bani and Bigazzi 2005). This clinical experience, albeit 
limited to a single patient, conﬁ  rms the ﬁ  ndings of Casten 
and colleagues and gives further momentum to future clinical 
studies in this direction.
Another clinical issue highlighting the vasoprotective role 
of RLX and its possible therapeutical use is pre-eclampsia, a 
disease of late pregnancy characterized by de novo occurrence 
of hypertension and proteinuria and by histopathological signs 
of peripheral and placental endothelial injury. Its occurrence 
is the leading cause of pre-term delivery and fetal growth 
restriction and predisposes both the offspring and the mother 
to subsequent cardiovascular risk (Smith et al 2001). Recently, 
compelling evidence has been brought forth suggesting a 
major role for soluble growth factor receptor fms-like tyrosine 
kinase 1, asymmetric dimethyl arginine and autoantibodies in 
the pathophysiology of pre-eclampsia. These molecules are 
present at abnormally high levels in the blood of pre-eclamptic 
women and lead to inactivation of circulating pro-angiogenic 
factors, inhibition of endothelial NO biosynthesis and stimula-
tion of angiotensin receptors, thereby causing pre-eclampsia 
(Davison et al 2004). As RLX can increase renal vasodilation 
and hyperﬁ  ltration, reduce myogenic reactivity of small renal 
arteries through activation of the endothelin B receptor-
NO pathway (Danielson et al 1999, 2000; Novak et al 
2001) and stimulate endothelial NO generation (Bani et al 
1998a; Failli et al 2001; Quattrone et al 2004), it appears Vascular Health and Risk Management 2008:4(3) 522
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the perfect candidate to counteract the pathogenic events 
of pre-eclampsia. To test this hypothesis a randomized, 
double-blind, placebo controlled clinical trial is currently in 
progress in the United States (www.clinicaltrials.gov; No 
NCT00333307) sponsored by BAS Medical, owner of the 
patent for human recombinant RLX. Hopefully, this study 
could provide exciting new suggestions for the possible clini-
cal use of RLX in pre-eclamptic patients.
Concluding remarks
The studies that I have brieﬂ  y summarized in the above para-
graphs offer clear-cut evidence that RLX has speciﬁ  c effects 
on the vascular and blood cells which may help counteract 
the different pathogenic aspects of CVD. Many clues also 
suggest that RLX could be the elusive ovarian hormone 
involved in the protection of fertile women from CVD. The 
experimental studies, especially those performed in animal 
models of vascular dysfunction, provide background to cur-
rent and future clinical trials aimed at exploring the broad 
therapeutic potential of human recombinant RLX as a new 
cardiovascular drug.
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